RxDoctor Payments Data

Sana Habib, MD

Allergy & Immunology · Washington, DCNPI 1629431747

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.4% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AstraZeneca at 26.5% of the total. 2025 is the largest year on record at $2,762, more than ten times the $260 reported in 2022. That places this record below the midpoint for allergy & immunology clinicians in DC, where the typical reported total is $4,220.

$3,775in general payments, 2019–2025

Across 115 payments — averaging $32.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Sanofi$971
  • Regeneron Healthcare Solutions, Inc.$243
  • Amgen$234
  • Pfizer$208
  • Novartis$196
  • plus $920 from 15 others

What the payments were for

  • Food & beverage$3,67597%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,775 in reported general payments places this provider in the 45th percentile of 20 allergy & immunology providers in District of Columbia.

See all allergy & immunology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$1,709
Medicare patients
13
Services billed
139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Azelastine Hcl71$2,597
Azelastine-FluticasoneAzelastine/Fluticasone13$1,178
Fluticasone Propionate68$1,093
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$1,071
Albuterol Sulfate HfaAlbuterol Sulfate37$1,059
Montelukast Sodium29$493
Ipratropium Bromide22$416
Famotidine24$244
Omeprazole25$220
Levocetirizine Dihydrochloride12$191

Paid to pharmacies, not to this prescriber.

Other allergy & immunology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →